Positive topline results were announced from a phase 3 study evaluating the immunogenicity and safety of Prevnar 20TM (pneumococcal 20-valent conjugate vaccine) coadministered with a booster dose of the Pfizer-BioNTech COVID-19 vaccine in adults 65 years of age and older.

The randomized, double-blind study (ClinicalTrials.gov Identifier: NCT04887948) recruited adults from the phase 3 Pfizer-BioNTech COVID-19 vaccine trial who received their second dose of the vaccine at least 6 months prior to entering the coadministration study. Patients were randomly assigned to receive Prevnar 20 with a dose of the Pfizer-BioNTech COVID-19 vaccine (n=190), Prevnar 20 with placebo (n=191), or Pfizer-BioNTech COVID-19 vaccine with placebo (n=189) at the same visit.

Results showed that similar responses were elicited for all 20 serotypes of Prevnar 20 whether it was administered with a dose of the Pfizer-BioNTech COVID-19 vaccine or placebo. Moreover, the responses elicited to a booster dose of the Pfizer-BioNTech COVID-19 vaccine were comparable when administered with Prevnar 20 or placebo. No new safety concerns were observed with coadministration.

“These new safety and immunogenicity data provide further evidence supporting the potential to administer Prevnar 20 and the Pfizer-BioNTech COVID-19 vaccine at the same time, thereby reducing the number of visits adults make to their doctor’s office or pharmacy for recommended immunization,” said Kathrin U. Jansen, PhD, Senior Vice President and Head of Vaccine Research & Development, Pfizer.


Positive top-line results of Pfizer’s phase 3 study exploring coadministration of Prevnar 20™ with Pfizer-BioNTech COVID-19 vaccine in older adults released. News release. Pfizer Inc. Accessed January 12, 2022. https://www.businesswire.com/news/home/20220112005278/en/Positive-Top-Line-Results-of-Pfizer%E2%80%99s-Phase-3-Study-Exploring-Coadministration-of-PREVNAR-20%E2%84%A2-With-Pfizer-BioNTech-COVID-19-Vaccine-in-Older-Adults-Released